Bergenbio ASA
OTC:BRRGF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BRRGF's latest stock split occurred on Jan 20, 2026
The company executed a 1-for-100 stock split, meaning that for every 100 shares held, investors received 1 new share.
Before the split, BRRGF traded at 0.0001 per share. Afterward, the share price was about 97.094.
The adjusted shares began trading on Jan 20, 2026. This was BRRGF's 2nd stock split, following the previous one in May 30, 2024.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 23, 2026
|
|
Red Sky Energy Ltd
ASX:ROG
|
5-for-4
x1.25
|
0.002 0.0016 AUD | 0.002 0.002 AUD |
|
Apr 23, 2026
|
J
|
Jiusheng Electric Co Ltd
SZSE:301082
|
1-for-1
x1
|
17.33 13.2508 CNY | 12.9 12.9 CNY |
|
Apr 23, 2026
|
S
|
Saudee Group Bhd
KLSE:SAUDEE
|
1-for-10
/10
|
0.01 0.1 MYR | 0.09 0.09 MYR |
|
Apr 23, 2026
|
|
Focus Technology Co Ltd
SZSE:002315
|
1-for-1
x1
|
44.3999 33.4538 CNY | 32 32 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
ROG
002315
Bergenbio ASA
Glance View
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
